Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective.

Betacoronavirus Bile Duct Neoplasms / therapy COVID-19 Carcinoma, Hepatocellular / pathology Cholangiocarcinoma / therapy Clinical Decision-Making Coronavirus Infections / epidemiology Humans Liver Neoplasms / pathology Neoplasm Staging Pandemics Patient Care Team Pneumonia, Viral / epidemiology Risk Factors SARS-CoV-2

Journal

The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683

Informations de publication

Date de publication:
08 2020
Historique:
received: 08 04 2020
revised: 01 05 2020
accepted: 01 05 2020
pubmed: 9 6 2020
medline: 28 7 2020
entrez: 9 6 2020
Statut: ppublish

Résumé

Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

Identifiants

DOI: 10.1016/S2468-1253(20)30182-5 PMID: 32511951 PMC: PMC7274990
pubmed: 32511951
pii: S2468-1253(20)30182-5
doi: 10.1016/S2468-1253(20)30182-5
pmc: PMC7274990
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

765-775

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

J Clin Oncol. 2016 Feb 10;34(5):452-9
pubmed: 26628466
Nat Rev Endocrinol. 2020 Jul;16(7):341-342
pubmed: 32327737
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
J Vasc Interv Radiol. 2015 Jul;26(7):943-8
pubmed: 25899049
Radiology. 2014 Mar;270(3):900-9
pubmed: 24475823
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
Hepatology. 2020 Nov;72(5):1654-1665
pubmed: 32017165
Ann Oncol. 2020 Aug;31(8):1084-1085
pubmed: 32330540
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Transpl Int. 2008 Mar;21(3):247-54
pubmed: 18028264
J Clin Oncol. 2016 Jan 20;34(3):219-26
pubmed: 26503201
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Oncol. 2020 May;21(5):633
pubmed: 32325021
Eur J Surg Oncol. 2015 Jan;41(1):120-7
pubmed: 25449754
Radiat Oncol. 2013 Oct 27;8:250
pubmed: 24160944
Front Oncol. 2019 May 31;9:457
pubmed: 31214502
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Hepatology. 2016 Dec;64(6):2077-2088
pubmed: 27178646
J Hepatol. 2016 Nov;65(5):938-943
pubmed: 27266618
Int J Hepatol. 2011;2011:791013
pubmed: 22135750
AJR Am J Roentgenol. 2011 Feb;196(2):W205-9
pubmed: 21257864
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Ann Surg. 2008 Jul;248(1):84-96
pubmed: 18580211
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Int J Cancer. 2018 Apr 15;142(8):1671-1675
pubmed: 29114851
J Hepatol. 2017 Jul;67(1):92-99
pubmed: 28257902
J Hepatol. 2020 Jul;73(1):121-129
pubmed: 32165253
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Gastroenterology. 2020 Jun;158(8):2024-2027
pubmed: 32314563
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1041-7
pubmed: 24661657
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Br J Surg. 2018 Jun;105(7):839-847
pubmed: 28858392
JAMA Oncol. 2018 May 1;4(5):661-669
pubmed: 29543938
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
Immunotherapy. 2020 Apr;12(5):269-273
pubmed: 32212881
J Clin Oncol. 2017 Nov 1;35(31):3575-3581
pubmed: 28872925
Surg Endosc. 2019 May;33(5):1451-1458
pubmed: 30203200
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533
pubmed: 32278366
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
J Hepatol. 2020 Jun;72(6):1151-1158
pubmed: 32145255
World J Gastroenterol. 2019 Apr 7;25(13):1550-1559
pubmed: 30983815
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Hepatobiliary Surg Nutr. 2017 Apr;6(2):105-116
pubmed: 28503558
Adv Radiat Oncol. 2020 Apr 01;5(4):573-574
pubmed: 32292838
Clin Microbiol Rev. 2019 Sep 11;32(4):
pubmed: 31511250
Transpl Int. 2010 Mar 1;23(3):299-306
pubmed: 19843294
J Clin Oncol. 2013 Nov 1;31(31):3980-6
pubmed: 24062394
Clin Mol Hepatol. 2018 Mar;24(1):1-9
pubmed: 29249129
J Infect Chemother. 2017 Nov;23(11):769-773
pubmed: 28545936
Jpn J Clin Oncol. 2006 Apr;36(4):212-7
pubmed: 16613896
PLoS One. 2013 Nov 08;8(11):e79854
pubmed: 24255719

Auteurs

Aisling Barry (A)

Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada. Electronic address: aisling.barry@rmp.uhn.ca.

Smith Apisarnthanarax (S)

Seattle Cancer Care Alliance, and Department of Radiation Oncology, University of Washington, Seattle, WA, USA.

Grainne M O'Kane (GM)

Department of Medical Oncology and Haematology, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

Gonzalo Sapisochin (G)

Princess Margaret Cancer Centre, and Department of Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

Robert Beecroft (R)

Department of Medical Imaging, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

Riad Salem (R)

Department of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Sang Min Yoon (SM)

Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Young-Suk Lim (YS)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

John Bridgewater (J)

UCL Cancer Institute, University College London, London, UK.

Brian Davidson (B)

Department of Surgical Biotechnology, UCL Division of Surgery and Interventional Science, University College London, London, UK.

Marta Scorsetti (M)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Luigi Solbiati (L)

Radiology Department, Humanitas Clinical and Research Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Adam Diehl (A)

Department of Medical Oncology, University of Washington, Seattle, WA, USA.

Pablo Munoz Schuffenegger (PM)

Radiation Oncology Unit, Department of Hematology Oncology, Pontifical Catholic University of Chile, Santiago, Chile.

Jonathan G Sham (JG)

Department of Surgery, University of Washington, Seattle, WA, USA.

David Cavallucci (D)

Department of Surgery, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia.

Zita Galvin (Z)

Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

Laura A Dawson (LA)

Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

Maria A Hawkins (MA)

UCL Cancer Institute, University College London, London, UK; Department of Medical Physics and Biomedical Engineering, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Management of primary hepatic malignancies...
questionsmedicales.fr › Maladies de l'appareil digestif › Tumeurs de l'appareil digestif › Tumeurs des voies biliaires › Tumeurs des canaux biliaires › Management of primary hepatic malignancies...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Management of primary hepatic malignancies...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Management of primary hepatic malignancies...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Cholangiocarcinome › Management of primary hepatic malignancies...
questionsmedicales.fr › Diagnostic › Prise de décision clinique › Management of primary hepatic malignancies...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Nidovirales › Infections à Coronaviridae › Infections à coronavirus › Management of primary hepatic malignancies...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Management of primary hepatic malignancies...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Management of primary hepatic malignancies...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Management of primary hepatic malignancies...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Management of primary hepatic malignancies...
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Équipe soignante › Management of primary hepatic malignancies...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › Management of primary hepatic malignancies...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Management of primary hepatic malignancies...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Management of primary hepatic malignancies...